Group 1 - The core product of Zhongke Baike (Tianjin) Biopharmaceutical Co., Ltd. is a recombinant cat interferon, which is a new type of veterinary drug that will soon enter the market, filling a gap in domestic veterinary medicine in China [3] - The company has expanded its research and quality inspection center from 200 square meters to 2000 square meters after relocating to the Tianjin Zhongguancun Science and Technology City, and has established two core technology platforms for recombinant protein drug research and vaccine industrialization [4] - Since the relocation, the company has obtained over 20 patents and is accelerating the launch of various pet medications, entering a "fast track" of development [4] Group 2 - The Yunfei Pharmaceutical R&D and production base project is under construction and is expected to be completed and operational by October 2026, featuring laboratories for chemical drug organic synthesis and drug analysis [6] - The chairman of Yunfei Biopharmaceutical (Tianjin) Co., Ltd. expressed confidence in achieving an annual output value of 500 million yuan within three years after production begins [6] - The Tianjin Baodi District is focusing on enhancing the "class Zhongguancun" ecosystem to mature the "Beijing-Tianjin R&D, regional transformation" model, thereby increasing the technological content and development potential of the biopharmaceutical industry [6]
科技新城孕育生物医药“新势力”
Xin Hua She·2025-12-10 05:23